Turn Therapeutics (NASDAQ:TTRX) Stock Rating Lowered by Wall Street Zen

Turn Therapeutics (NASDAQ:TTRX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities analysts also recently issued research reports about the company. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Finally, Weiss Ratings lowered Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Turn Therapeutics Price Performance

TTRX opened at $9.80 on Friday. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50. The firm has a market capitalization of $291.94 million and a P/E ratio of -33.79. The company’s 50-day moving average is $9.17 and its 200 day moving average is $5.96. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Research analysts expect that Turn Therapeutics will post -0.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Ieq Capital LLC bought a new stake in shares of Turn Therapeutics in the 2nd quarter worth approximately $1,660,000. Bridgewater Advisors Inc. bought a new position in Turn Therapeutics during the second quarter valued at $242,000. DDFG Inc grew its holdings in Turn Therapeutics by 34.9% during the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after purchasing an additional 18,246 shares during the period. Tamar Securities LLC purchased a new stake in Turn Therapeutics in the fourth quarter worth $59,000. Finally, Wellington Shields & Co. LLC purchased a new stake in Turn Therapeutics in the fourth quarter worth $259,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.